Attached files

file filename
EX-10.7 - FORM OF 2007 EQUITY INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT FOR DIRECTOR - CTI BIOPHARMA CORPdex107.htm
10-Q - FORM 10-Q - CTI BIOPHARMA CORPd10q.htm
EX-10.6 - FORM OF 2007 EQUITY INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT FOR EMPLOYEE - CTI BIOPHARMA CORPdex106.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex312.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex311.htm
EX-10.5 - CO-DEVELOPMENT AND LICENSE AGREEMENT - CTI BIOPHARMA CORPdex105.htm

EXHIBIT 32

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, James A. Bianco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of Cell Therapeutics, Inc., that, to my knowledge, the Quarterly Report of Cell Therapeutics, Inc. on Form 10-Q for the fiscal quarter ended March 31, 2011 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Cell Therapeutics, Inc.

A signed original of this written statement required by Section 906 has been provided to Cell Therapeutics, Inc. and will be retained by Cell Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Dated: April 26, 2011     By:   /s/ James A. Bianco, M.D
        James A. Bianco, M.D.
        Chief Executive Officer

I, Louis A. Bianco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of Cell Therapeutics, Inc., that, to my knowledge, the Quarterly Report of Cell Therapeutics, Inc. on Form 10-Q for the fiscal quarter ended March 31, 2011 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Cell Therapeutics, Inc.

A signed original of this written statement required by Section 906 has been provided to Cell Therapeutics, Inc. and will be retained by Cell Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Dated: April 26, 2011     By:   /s/ Louis A. Bianco
        Louis A. Bianco
        Executive Vice President,
        Finance and Administration